XLY Stock Overview
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada.
+ 1 more risk
Auxly Cannabis Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.08|
|52 Week High||CA$0.35|
|52 Week Low||CA$0.065|
|1 Month Change||14.29%|
|3 Month Change||-48.39%|
|1 Year Change||-65.22%|
|3 Year Change||-91.58%|
|5 Year Change||-89.33%|
|Change since IPO||-85.46%|
Recent News & Updates
Health Check: How Prudently Does Auxly Cannabis Group (TSE:XLY) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
|XLY||CA Pharmaceuticals||CA Market|
Return vs Industry: XLY exceeded the Canadian Pharmaceuticals industry which returned -66.3% over the past year.
Return vs Market: XLY underperformed the Canadian Market which returned -1.2% over the past year.
|XLY Average Weekly Movement||15.8%|
|Pharmaceuticals Industry Average Movement||13.4%|
|Market Average Movement||10.8%|
|10% most volatile stocks in CA Market||19.4%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: XLY is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: XLY's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. It offers cannabis products under various forms, including vape catridges, dried flower, concentrates, chocolates, soft chews, oil drops, capsules, topicals, and hard candy under the brands KOLAB PROJECT, Dosecann, BACK FORTY, and Foray.
Auxly Cannabis Group Fundamentals Summary
|XLY fundamental statistics|
Is XLY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XLY income statement (TTM)|
|Cost of Revenue||CA$76.67m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 15, 2022
|Earnings per share (EPS)||-0.083|
|Net Profit Margin||-77.53%|
How did XLY perform over the long term?See historical performance and comparison
Is XLY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XLY?
Other financial metrics that can be useful for relative valuation.
|What is XLY's n/a Ratio?|
Price to Sales Ratio vs Peers
How does XLY's PS Ratio compare to its peers?
|XLY PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
NUMI Numinus Wellness
RWB Red White & Bloom Brands
IMCC IM Cannabis
LOVE Cannara Biotech
XLY Auxly Cannabis Group
Price-To-Sales vs Peers: XLY is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (7.8x).
Price to Earnings Ratio vs Industry
How does XLY's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs Industry: XLY is good value based on its Price-To-Sales Ratio (0.7x) compared to the Canadian Pharmaceuticals industry average (1.7x)
Price to Sales Ratio vs Fair Ratio
What is XLY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.7x|
|Fair PS Ratio||2.2x|
Price-To-Sales vs Fair Ratio: XLY is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).
Share Price vs Fair Value
What is the Fair Price of XLY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: XLY (CA$0.08) is trading below our estimate of fair value (CA$3.3)
Significantly Below Fair Value: XLY is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Auxly Cannabis Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XLY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XLY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XLY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XLY's revenue (28.7% per year) is forecast to grow faster than the Canadian market (6.3% per year).
High Growth Revenue: XLY's revenue (28.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XLY's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Auxly Cannabis Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XLY is currently unprofitable.
Growing Profit Margin: XLY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XLY is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.
Accelerating Growth: Unable to compare XLY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XLY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (72.5%).
Return on Equity
High ROE: XLY has a negative Return on Equity (-43.44%), as it is currently unprofitable.
Discover strong past performing companies
How is Auxly Cannabis Group's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: XLY's short term assets (CA$125.2M) exceed its short term liabilities (CA$51.4M).
Long Term Liabilities: XLY's short term assets (CA$125.2M) do not cover its long term liabilities (CA$192.4M).
Debt to Equity History and Analysis
Debt Level: XLY's net debt to equity ratio (91.6%) is considered high.
Reducing Debt: XLY's debt to equity ratio has increased from 14.7% to 101.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XLY has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: XLY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 28.7% each year
Discover healthy companies
What is Auxly Cannabis Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XLY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XLY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XLY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XLY's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as XLY has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hugo Alves (50 yo)
Mr. Hugo M. Alves serves as Chief Executive Officer of Auxly Cannabis Group Inc. since August 27, 2019 and is a Co-Founder of Auxly Cannabis Group. Mr. Alves served as Director at BC Craft Supply Co. Ltd....
CEO Compensation Analysis
Compensation vs Market: Hugo's total compensation ($USD2.20M) is above average for companies of similar size in the Canadian market ($USD186.89K).
Compensation vs Earnings: Hugo's compensation has increased whilst the company is unprofitable.
Experienced Management: XLY's management team is considered experienced (2.6 years average tenure).
Experienced Board: XLY's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.
Auxly Cannabis Group Inc.'s employee growth, exchange listings and data sources
- Name: Auxly Cannabis Group Inc.
- Ticker: XLY
- Exchange: TSX
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$72.556m
- Shares outstanding: 906.94m
- Website: https://auxly.com
Number of Employees
- Auxly Cannabis Group Inc.
- 777 Richmond Street West
- Unit 002
- M6J 0C2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.